S100A14 Facilitates Pancreatic Cancer Progression via S100A16-Mediated p53 Suppression
Oncology Research · 2026
DOI: 10.32604/or.2025.070207 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2026. Verfasst von Pingping Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatopancreatobiliary Surgery, The First People's Hospital of Yunnan Province, Kunming, 650032, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Tumor Suppressor Protein p53, S100 Proteins. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatopancreatobiliary Surgery, The First People's Hospital of Yunnan Province, Kunming, 650032, China.
- Department of Hepatopancreatobiliary Surgery, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, 650032, China.
Zitieren
APA
Hu, P., Fei, Z., Bai, J., Wang, Z., & Jin, Y. (2026). S100A14 Facilitates Pancreatic Cancer Progression via S100A16-Mediated p53 Suppression. Oncology Research. https://doi.org/10.32604/or.2025.070207
Vancouver
Hu P, Fei Z, Bai J, Wang Z, Jin Y. S100A14 Facilitates Pancreatic Cancer Progression via S100A16-Mediated p53 Suppression. Oncology Research. 2026. doi:10.32604/or.2025.070207
BibTeX
@article{Hu2026,
author = {Hu, Pingping and Fei, Zhenhao and Bai, Jianhua and Wang, Zhiwen and Jin, Yun},
title = {S100A14 Facilitates Pancreatic Cancer Progression via S100A16-Mediated p53 Suppression},
journal = {Oncology Research},
year = {2026},
doi = {10.32604/or.2025.070207}
}
EUVIMED